Details for Patent: 9,968,659

Which drugs does patent 9,968,659 protect, and when does it expire?

Patent 9,968,659 protects SAXENDA and VICTOZA and is included in two NDAs.

Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in twenty-four countries.

Summary for Patent: 9,968,659

Patent landscape, scope, and claims:

Title:	Liraglutide in cardiovascular conditions
Abstract:	The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.
Inventor(s):	Rasmussen; Soeren (Copenhagen, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	15/401,651
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,968,659
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,968,659

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	SAXENDA	liraglutide	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes					Y
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes					Y

International Family Members for US Patent 9,968,659

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017225841
Brazil	112018067344
Canada	3013532